€18.72
1.47% today
Xetra, Nov 17, 11:13 am CET
ISIN
DE000A3ENQ51
Symbol
1SXP
Index

SCHOTT Pharma Stock price

€19.00
-1.00 5.00% 1M
-7.00 26.92% 6M
-6.16 24.48% YTD
-8.96 32.05% 1Y
-12.30 39.30% 3Y
-12.30 39.30% 5Y
-12.30 39.30% 10Y
-12.30 39.30% 20Y
Xetra, Closing price Fri, Nov 14 2025
+0.14 0.74%
ISIN
DE000A3ENQ51
Symbol
1SXP
Index

New AI Insights on SCHOTT Pharma Insights AI Insights on SCHOTT Pharma

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
€2.8b
Enterprise Value
€2.9b
Net debt
€44.8m
Cash
€41.2m
Shares outstanding
151.0m
Valuation (TTM | estimate)
P/E
19.6 | 18.6
P/S
2.9 | 2.8
EV/Sales
3.0 | 2.9
EV/FCF
56.6
P/B
3.3
Dividends
DPS
€0.16
Yield 1Y | 5Y
0.8% | 0.2%
Growth 1Y | 5Y
6.7% | -
Payout 1Y | 3Y
15.2% | 5.3%
Increased
2 Years
Financials (TTM | estimate)
Revenue
€975.7m | €1.0b
EBITDA
€264.4m | €281.1m
EBIT
€189.4m | €205.7m
Net Income
€147.0m | €154.3m
Free Cash Flow
€51.0m
Growth (TTM | estimate)
Revenue
2.9% | 5.5%
EBITDA
14.8% | 9.8%
EBIT
11.8% | 7.7%
Net Income
-2.1% | 2.9%
Free Cash Flow
123.4%
Margin (TTM | estimate)
Gross
33.7%
EBITDA
27.1% | 27.8%
EBIT
19.4%
Net
15.1% | 15.3%
Free Cash Flow
5.2%
Financial Health
Equity Ratio
54.8%
Return on Equity
19.0%
ROCE
17.0%
ROIC
12.9%
Debt/Equity
0.1
More
EPS
€1.0
FCF per Share
€0.3
Short interest
-
Employees
5k
Rev per Employee
€200.0k
Show more

Is SCHOTT Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

SCHOTT Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a SCHOTT Pharma forecast:

15x Buy
79%
3x Hold
16%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a SCHOTT Pharma forecast:

Buy
79%
Hold
16%
Sell
5%

Financial data from SCHOTT Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
976 976
3% 3%
100%
- Direct Costs 646 646
3% 3%
66%
329 329
2% 2%
34%
- Selling and Administrative Expenses 128 128
2% 2%
13%
- Research and Development Expense 27 27
0% 0%
3%
264 264
15% 15%
27%
- Depreciation and Amortization 75 75
23% 23%
8%
EBIT (Operating Income) EBIT 189 189
12% 12%
19%
Net Profit 147 147
2% 2%
15%

In millions EUR.

Don't miss a Thing! We will send you all news about SCHOTT Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SCHOTT Pharma Stock News

AD HOC NEWS
13 days ago
SCHOTT Pharma AG & Co. KGaA / DE000A3ENQ51
AD HOC NEWS
13 days ago
SCHOTT Pharma AG & Co. KGaA / DE000A3ENQ51
AD HOC NEWS
13 days ago
SCHOTT Pharma AG & Co. KGaA / DE000A3ENQ51
More SCHOTT Pharma News

Company Profile

Head office Germany
CEO Andreas Reisse
Employees 4,775
Founded 2022
Website www.schott-pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today